Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

BACKGROUND: The epidermal growth factor receptor (EGFR) is an established target for anti-cancer treatment in different tumour types. Two different strategies have been explored to inhibit this pivotal molecule in epithelial cancer development: small molecules TKIs and monoclonal antibodies. ErbB/HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavazzoni, Andrea, Alfieri, Roberta R, Cretella, Daniele, Saccani, Francesca, Ampollini, Luca, Galetti, Maricla, Quaini, Federico, Graiani, Gallia, Madeddu, Denise, Mozzoni, Paola, Galvani, Elena, La Monica, Silvia, Bonelli, Mara, Fumarola, Claudia, Mutti, Antonio, Carbognani, Paolo, Tiseo, Marcello, Barocelli, Elisabetta, Petronini, Pier Giorgio, Ardizzoni, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577499/
https://www.ncbi.nlm.nih.gov/pubmed/23234355
http://dx.doi.org/10.1186/1476-4598-11-91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577499/
https://www.ncbi.nlm.nih.gov/pubmed/23234355
http://dx.doi.org/10.1186/1476-4598-11-91

Ejemplares similares